Protalix BioTherapeutics, Inc. (NYSE:PLX) Q2 2023 Earnings Conference Call August 7, 2023 8:30 AM ET Company Participants Charles Padala - IR Dror Bashan - President and CEO Eyal Rubin - SVP and CFO Conference Call Participants Boobalan Pachaiyappan - H.C. Wainwright John Vandermosten - Zacks Unidentified Analyst - Private Investor Operator Good morning, ladies and gentlemen and welcome to the Protalix BioTherapeutics Conference for Second Quarter 2023 Financial Business Results. As a reminder, this confere ...

Or UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 001-33357 (Commission file number) PROTALIX BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware __65-0643773__ (State o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 001-33357 (Commission file number) PROTALIX BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware __65-0643773__ (State or ...

Protalix Biotherapeutics, Inc. (NYSE:PLX) Q1 2023 Earnings Conference Call May 4, 2023 8:30 AM ET Company Participants Charles Padala - IR Dror Bashan - President, CEO & Director Eyal Rubin - SVP, CFO, Treasurer & Corporate Secretary Conference Call Participants John Vandermosten - Zacks Operator Good morning, ladies and gentlemen, and welcome to the Protalix BioTherapeutics First Quarter 2023 Financial Business Results Conference Call. As a reminder, this conference is being recorded. I will now turn the ...

Protalix BioTherapeutics Inc. (NYSE:PLX) Q4 2022 Earnings Conference Call February 27, 2023 8:30 AM ET Company Participants Dror Bashan - President, Chief Executive Officer Eyal Rubin - Senior Vice President, Chief Financial Officer Monique Kosse - LifeSci Advisors Conference Call Participants Boobalan Pachaiyappan - HC Wainwright John Vandermosten - Zacks Small Cap Research Operator Good morning ladies and gentlemen and welcome to the Protalix full year 2022 earnings call. As a reminder, this conference ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K FOR ANNUAL AND TRANSITION REPORTS PURSUANT TO SECTIONS 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 001-33357 (Commission file number) P ...

Protalix BioTherapeutics, Inc. CORPORATE UPDATE | FEBRUARY 2020 Note Regarding Forward-Looking Statements This presentation (the "Presentation") contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements, including, among others, statements regarding expectations as to regulatory approvals, market opportunity for, and potential sales of, the Company's product and product candid ...

Protalix BioTherapeutics, Inc. CORPORATE UPDATE | FEBRUARY 2020 Note Regarding Forward-Looking Statements This presentation (the "Presentation") contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements, including, among others, statements regarding expectations as to regulatory approvals, market opportunity for, and potential sales of, the Company's product and product candid ...